PLATINUM-SENSITIVE OVARIAN CARCINOMA
Clinical trials for PLATINUM-SENSITIVE OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-SENSITIVE OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-SENSITIVE OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for recurrent ovarian cancer in early trial
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (berzosertib) to standard chemotherapy (carboplatin and gemcitabine) is safe and effective for people with ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 participan…
Matched conditions: PLATINUM-SENSITIVE OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study compares two treatments for women with ovarian, fallopian tube, or peritoneal cancer that has come back after initial therapy. One group gets olaparib alone, the other gets olaparib plus tremelimumab. Olaparib blocks cancer cells from repairing themselves, while tremel…
Matched conditions: PLATINUM-SENSITIVE OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: PLATINUM-SENSITIVE OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC